Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects

Journal of Clinical Pharmacology

Volumn 49, Issue 6, 2009, Pages 634-642

  Modi, Nishit B ^a   Nath, Rajneesh ^a   Staehr, Peter ^a,c   Gupta, Suneel K ^a   Aquilina, Joseph W ^b   Rivas, David ^b  

^a ALZA CORPORATION   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c CV THERAPEUTICS INC   (United States)

Author keywords

Dapoxetine; Premature ejaculation; QT interval

Indexed keywords

DAPOXETINE; MOXIFLOXACIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PREMATURE EJACULATION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; AZA COMPOUNDS; BENZYLAMINES; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; HEART; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; QUINOLINES; SEROTONIN UPTAKE INHIBITORS;

EID: 67049119564     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009333486     Document Type: Article

References (20)

1. Patrick DL, Althof SE, Pryor JL, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med. 2005;2:358-367.
2. Symonds T, Roblin D, Hart K, Althof S. How does premature ejaculation impact a man's life? J Sex Marital Ther. 2003;29: 361-370.
3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281: 537-544.
4. Rowland D, Perelman M, Althof S, et al. Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med. 2004;1:225-232.
5. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51:816-824.
6. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydro-chloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006;46:301-309.
7. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation: integrated analysis of two randomized, double-blind, placebo-controlled trials. Lancet. 2006;368(9539):929-937.
8. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial [published online ahead of print November 18, 2008]. BJU Int. doi:10.1111/ j.1464-410X.2008.08165.X. 2008.
9. Hellstrom W, Althof S, Gittelman M, et al. Dapoxetine for the treatment of men with premature ejaculation (PE): dose-finding analysis. J Urol. 2005;173(suppl 4):238. Abstract 877.
10. Buvat J, Tesfaye F, Rothman M, Rivas D, Giuliano F. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled trial in 22 countries. Eur Urol. In press.
11. McMahon C, Park NC, Zhao Y, Rothman M, Rivas D. Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Oral presentation at: the 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine; October 6-10, 2007; Jeju, Korea. Abstract OS05-06.
12. Bazett HC. An analysis of time relations of electrocardiograms. Heart. 1920;7:353-367.
13. Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Med Scand. 1920;53:469-486.
14. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73:292-303.
15. Hochberg HM, Kanter D, Houser VP. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one year's experience. Pharmacopsychiatry. 1995;28:253-256.
16. Strik JJ, Honig A, Lousberg R, Cheriex EC, Van Praag HM. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients. Int Clin Psycho-pharmacol. 1998;13:263-267.
17. Pacher P, Ungvari Z, Kecskemeti V, Furst S. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr Med Chem. 1998;5:381-390.
18. Combes A, Peytavin G, Theron D. Conduction disturbances associated with venlafaxine. Ann Intern Med. 2001;134:166-167.
19. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit. 2001;23:435-440.
20. United States Food and Drug Administration. Guidance for Industry. E14. Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, http:// www.fda.gov/cber/gdlns/ichel4qtc.htm#ii. Accessed January 5, 2009.